Nanobody-as versatile tool emerging in autoimmune diseases

Ling Wang; Ran Luo; Weilang Zhang; Hanyu Jiang; Yongkang Yu; Wenhu Zhou; Fan Zhang; Jian Ma; Lin Mei

Smart Materials in Medicine (Dec 2024)

Nanobody-as versatile tool emerging in autoimmune diseases

Ling Wang,
Ran Luo,
Weilang Zhang,
Hanyu Jiang,
Yongkang Yu,
Wenhu Zhou,
Fan Zhang,
Jian Ma,
Lin Mei

Affiliations

Ling Wang: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China
Ran Luo: State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300192, China
Weilang Zhang: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China; State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300192, China
Hanyu Jiang: Guangdong Second Provincial General Hospital, Guangzhou, 510317, China
Yongkang Yu: School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 21 Nanyang Link, Singapore, 637371, Singapore
Wenhu Zhou: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China; Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, School of Pharmaceutical Science, Changsha Medical University, Changsha, 410219, China
Fan Zhang: State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300192, China; Corresponding author.
Jian Ma: Department of Immunology, Harbin Medical University, Harbin, 150080, China; Corresponding author.
Lin Mei: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China; State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300192, China; Corresponding author. Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.

Journal volume & issue: Vol. 5, no. 4
pp. 501 – 513

Abstract

Read online

Nanobody (Nb) is derived from the variable domain of heavy-chain antibody (HCAb), naturally displaying notable properties like nano-scale size, exceptional stability, high specificity, low immunogenicity, and cryptic epitope accessibility. These features contribute to its great therapeutic potential as a valuable research tool across diverse diseases, especially autoimmune diseases (AIDs). Caplacizumab (Cablivi®) is the first nanobody drug approved for treating acquired thrombotic thrombocytopenic purpura (aTTP). This review summarizes the biomolecular structure, usage of Nb as a foundation of recombinant constructs, and biochemical properties of nanobodies. As attractive therapeutic candidates, many clinical trials of Nbs have been conducted, elucidating potential therapeutic strategies for AIDs. Therefore, the preclinical development and application of Nbs in AIDs are emphasized throughout this review.

Published in Smart Materials in Medicine

ISSN: 2590-1834 (Online)
Publisher: KeAi Communications Co., Ltd.
Country of publisher: China
LCC subjects: Technology
Website: https://www.keaipublishing.com/en/journals/smart-materials-in-medicine/

About the journal

Abstract

Keywords